Topiramate
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Topiramate(TPM)是一种新型抗惊厥药物,是一种广泛使用的抗癫痫药。据报道,该药物与多种离子通道类型相互作用,如AMPA/红藻氨酸受体/电压敏感的Na+通道/NMDA受体和GABA受体[1,2]。
体外实验:在大鼠基底外侧杏仁核的主要神经元中,低浓度topiramate选择性抑制由包含GluR5亚基的kainate受体介导的药理学分离的兴奋性突触电流,IC50值大约为0.5 μM。Topiramate也部分抑制AMPA受体介导的EPSCs,具有较低的功效[1]。在分离的皮层切片中,低浓度TPM(25-30 μM)轻微抑制Na+电流的持续分数,并减少Na+依赖性的持久动作电位,其可以在Ca2+和K+电流阻断之后的V锥体神经元中诱发。TPM(100 μM)对电压依赖性的激活无效,但诱导稳态INaf失活曲线向左偏移[3]。
在体实验:TPM显著改善24小时神经功能缺损得分,低剂量为1.75 ± 0.5,高剂量为1.17 ± 0.41,两种剂量的p值小于0.05。对照组梗塞面积为54.2 ± 9.0%,神经行为评分为2.67 ± 0.52,与对照相比,低剂量药物致使梗塞体积百分比减少,为22.9 ± 8.9%(p = 0.002),高剂量的梗塞百分比为7.6 ± 3.4%(p < 0.001)。用较高剂量的TPM处理比低剂量诱导更多的神经保护(p < 0.05)。在大鼠局灶性缺血模型中,MCA栓塞后2小时,topiramate以剂量和使用依赖性方式产生神经保护作用[2]。在输注GluR5红藻氨酸受体的选择性激动剂ATPA诱导的阵挛性发作中,Topiramate(25-100 mg/kg,i.p)以剂量依赖性方式升高阵挛性发作的阈值[4]。Topiramate(i.p)以剂量依赖性方式有效抑制围产期缺氧诱导的急性发作,ED50为2.1 mg/kg [5]。Topiramate(20和40 mg/kg,i.p.)剂量依赖性地抑制强直和癫痫发作。在DBA/2小鼠中,topiramate抑制声音诱导的发作,ED50为8.6 mg/kg(p.o)[6]。
参考文献:
Gryder D S, Rogawski M A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons[J]. The Journal of neuroscience, 2003, 23(18): 7069-7074.
Yang Y, Shuaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization[J]. Brain research, 1998, 804(2): 169-176.
Taverna S, Sancini G, Mantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 288(3): 960-968.
Kaminski R M, Banerjee M, Rogawski M A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist[J]. Neuropharmacology, 2004, 46(8): 1097-1104.
Koh S, Jensen F E. Topiramate blocks perinatal hypoxia‐induced seizures in rat pups[J]. Annals of neurology, 2001, 50(3): 366-372.
Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice[J]. European journal of pharmacology, 1994, 254(1-2): 83-89.
Storage | Store at -20°C |
M.Wt | 339.36 |
Cas No. | 97240-79-4 |
Formula | C12H21NO8S |
Solubility | ≥16.95 mg/mL in DMSO; ≥2.22 mg/mL in H2O with ultrasonic; ≥24.1 mg/mL in EtOH |
Chemical Name | [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methyl sulfamate |
SDF | Download SDF |
Canonical SMILES | CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
神经元 |
制备方法 |
在DMSO中的溶解度大于10 mM。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。 |
反应条件 |
25 ~ 400 μM |
实验结果 |
在分离的神经元中,Topiramate呈剂量依赖性地抑制持续性钠电流。 |
动物实验 [2]: | |
动物模型 |
雄性NIH瑞士小鼠 |
给药剂量 |
25 ~ 100 mg/kg;腹腔注射 |
实验结果 |
在雄性NIH瑞士小鼠,静脉滴注TPA(GluR5红藻氨酸受体选择性激动剂)诱导阵挛性发作。Topiramate(5 ~ 100 mg/kg,腹腔注射)呈剂量依赖性地增加阵挛性发作的阈值。 |
其它注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999 Mar;288(3):960-8. [2]. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. |
质量控制和MSDS
- 批次: